Linearis Labs Secures Funding for Innovative Health Projects from Terry Fox Research Institute
In an exciting development for the health technology sector, Linearis Labs has been chosen to receive financial backing for two groundbreaking projects funded by the Terry Fox Research Institute (TFRI). Announced on September 16, 2026, these projects are among 14 funded across Canada under the Digital Health Innovation Fund (DHIF), which aims to enhance health data sharing through artificial intelligence (AI).
The Digital Health Innovation Fund is a key initiative led by TFRI's Digital Health Discovery Platform (DHDP). The total investment for these pioneering projects amounts to an impressive $40.9 million, enlisting 55 partners from various sectors across the nation to propel research in precision medicine through AI technologies.
TFRI's President and Scientific Director, Dr. Jim Woodgett, emphasized the importance of collaboration between research and business in driving innovation in the healthcare landscape. With a focus on data sharing and precision medicine, the funded projects represent a significant advancement in addressing complex health challenges such as cancer and neurodegenerative diseases.
Linearis Labs' two main projects include:
1. Multi-Omics Data to AI Disease Signature Discovery: In partnership with organizations such as MRM Proteomics, Simmunome, Jewish General Hospital/CIUSSS, and Nova Scotia Health, this project aims to utilize AI to interpret integrated genomic, proteomic, and metabolomic data. The goal is to predict tailored treatment options for patients suffering from lung, breast, or colorectal cancers. By focusing on the specific biological signatures associated with these types of cancer, researchers hope to facilitate earlier and more effective treatments for patients.
2. AI-Enabled Biomarker Discovery and Therapeutic Monitoring in Neurodegenerative Disease: This project, conducted alongside Nanil Therapeutics, aims to leverage secure health data and AI technologies to identify biomarkers that improve the study and monitoring of neurodegenerative diseases. By enhancing our understanding of biological signals, researchers aim to create better therapeutic strategies and tracking mechanisms for these complex diseases.
Alexandre Le Bouthillier, CEO of Linearis Labs, commented on the significance of these projects, stating that cancer and neurodegenerative diseases are intricate conditions requiring a multifaceted approach. He highlighted that relying solely on one type of data fails to capture the complete picture of these diseases. By blending various data sources through the DHDP’s federated learning infrastructure, which allows for analysis without data movement, researchers can maintain patient privacy while driving AI innovations.
Both initiatives will utilize the DHDP’s infrastructure, making it possible to collaboratively analyze data across institutions. This approach not only protects privacy but also cultivates new investment opportunities and potential breakthroughs in health science.
For further information about the funded projects and their collaborating organizations, readers can visit the DHDP website at www.dhdp.ca/projects.
As a part of its mission, Linearis aims to champion the development of essential discoveries to prevent, detect, and cure diseases, focusing on innovative, AI-driven life sciences initiatives. This commitment extends towards supporting growth in the healthcare sector through thorough investment in transformative projects. To learn more about Linearis Labs, please explore their website at www.linearis.com.
In summary, the funding awarded to Linearis Labs underscores a significant step toward improved healthcare solutions through AI, paving the way for more personalized and effective medicinal approaches.
The Digital Health Innovation Fund is a key initiative led by TFRI's Digital Health Discovery Platform (DHDP). The total investment for these pioneering projects amounts to an impressive $40.9 million, enlisting 55 partners from various sectors across the nation to propel research in precision medicine through AI technologies.
TFRI's President and Scientific Director, Dr. Jim Woodgett, emphasized the importance of collaboration between research and business in driving innovation in the healthcare landscape. With a focus on data sharing and precision medicine, the funded projects represent a significant advancement in addressing complex health challenges such as cancer and neurodegenerative diseases.
Linearis Labs' two main projects include:
1. Multi-Omics Data to AI Disease Signature Discovery: In partnership with organizations such as MRM Proteomics, Simmunome, Jewish General Hospital/CIUSSS, and Nova Scotia Health, this project aims to utilize AI to interpret integrated genomic, proteomic, and metabolomic data. The goal is to predict tailored treatment options for patients suffering from lung, breast, or colorectal cancers. By focusing on the specific biological signatures associated with these types of cancer, researchers hope to facilitate earlier and more effective treatments for patients.
2. AI-Enabled Biomarker Discovery and Therapeutic Monitoring in Neurodegenerative Disease: This project, conducted alongside Nanil Therapeutics, aims to leverage secure health data and AI technologies to identify biomarkers that improve the study and monitoring of neurodegenerative diseases. By enhancing our understanding of biological signals, researchers aim to create better therapeutic strategies and tracking mechanisms for these complex diseases.
Alexandre Le Bouthillier, CEO of Linearis Labs, commented on the significance of these projects, stating that cancer and neurodegenerative diseases are intricate conditions requiring a multifaceted approach. He highlighted that relying solely on one type of data fails to capture the complete picture of these diseases. By blending various data sources through the DHDP’s federated learning infrastructure, which allows for analysis without data movement, researchers can maintain patient privacy while driving AI innovations.
Both initiatives will utilize the DHDP’s infrastructure, making it possible to collaboratively analyze data across institutions. This approach not only protects privacy but also cultivates new investment opportunities and potential breakthroughs in health science.
For further information about the funded projects and their collaborating organizations, readers can visit the DHDP website at www.dhdp.ca/projects.
As a part of its mission, Linearis aims to champion the development of essential discoveries to prevent, detect, and cure diseases, focusing on innovative, AI-driven life sciences initiatives. This commitment extends towards supporting growth in the healthcare sector through thorough investment in transformative projects. To learn more about Linearis Labs, please explore their website at www.linearis.com.
In summary, the funding awarded to Linearis Labs underscores a significant step toward improved healthcare solutions through AI, paving the way for more personalized and effective medicinal approaches.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.